Study S000926

The Effect of Liraglutide Versus Placebo When Added to Basal Insulin Analogues With or Without Metformin in Subjects With Type 2 Diabetes

Name: LivingGLP1 adjudicated trial data and network meta-analysis results
Creator: Ahmad Sofi-Mahmudi
License: https://creativecommons.org/licenses/by/4.0/

Included trial: extracted data ClinicalTrials.gov record

Registration

Registration: NCT01617434
Study type: INTERVENTIONAL
Allocation: RANDOMIZED
Phase: PHASE3
Masking: DOUBLE
Status: COMPLETED
Enrollment: 451
Start: 2012-09
Primary completion: 2013-10
Lead sponsor: Novo Nordisk A/S
Conditions: Diabetes; Diabetes Mellitus, Type 2
Interventions: DRUG:liraglutide; DRUG:placebo
Results posted: TRUE
Secondary identifiers: EUDRACT_NUMBER:2011-002696-41; OTHER:U1111-1121-9874

Registered primary outcomes

Change in Glycosylated Haemoglobin (HbA1c) From Baseline to Week 26 [Week 0 to Week 26]

Linked records (3)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

Record	Title	Year	Design	Identifiers	Link basis
R0013169	IDegLira Versus Alternative Intensification Strategies in Patients with Type 2 Diabetes Inadequately Controlled on Basal Insulin Therapy. Freemantle N, Diabetes therapy : research, treatment and education of diabetes and related disorders	2015	Randomized trial	PMID 26582052 DOI	registry reference RESULT:26582052
R0026247	Efficacy and safety of liraglutide versus placebo added to basal insulin analogues (with or without metformin) in patients with type 2 diabetes: a randomized, placebo-controlled trial. Ahmann A, Diabetes, obesity & metabolism	2015	Randomized trial	PMID 26179619 DOI	registry reference RESULT:26179619
R0048403	LIRA-ADD2BASAL: Liraglutide Added to Basal Insulin Analogs Improves Glycemic Control Kelsey Mann, MD Conference Express	2014	Other trial	DOI	cites ClinicalTrials.gov:NCT01617434